CV Sciences (CVSI) Net Income (QoQ) (2011 - 2026)
CV Sciences (CVSI) Net Income (QoQ) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - |
| 10 | CV Sciences | 4.10 Mn | 3.84 Mn | 1.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -20.53% |
| Mar 31, 2026 | -499.38% |
| Dec 31, 2025 | 142.15% |
| Sep 30, 2025 | -46.36% |
| Jun 30, 2025 | -139.45% |
| Mar 31, 2025 | 76.56% |
| Dec 31, 2024 | -1.97% |
| Sep 30, 2024 | 21.92% |
| Jun 30, 2024 | 7.01% |
| Mar 31, 2024 | 28.88% |
| Dec 31, 2023 | -97.54% |
| Sep 30, 2023 | 65.30% |
| Jun 30, 2023 | -122.57% |
| Mar 31, 2023 | 1,012.96% |
| Dec 31, 2022 | 39.38% |
| Sep 30, 2022 | 61.14% |
| Jun 30, 2022 | -25.44% |
| Mar 31, 2022 | 76.12% |
| Dec 31, 2021 | -22,042.50% |
| Sep 30, 2021 | 98.87% |